Market Overview

Stifel Downgrades AutoZone, O'Reilly

Share:

In a report released Friday, Stifel analyst David Schick downgraded AutoZone (NYSE: AZO) and O'Reilly Automotive (NASDAQ: ORLY) from Buy to Hold.

No change in price target was given for either car part retailer; Stifel previously held a $570 price target for AutoZone and a $150 price for O'Reilly's

Analysts at Stifel believe AutoZone faced counter-cycle tailwinds in 2013 through the first half of 2014 and expect tailwinds to wind down over the next year.

Schick predicts weaker sales for O'Reilly for the company's upcoming quarter, despite its strong market effort in the near term. The note said recent retail sales for the sector slowed its heavy growth, currently up 3.3 percent year over year from February to April, and increased by 0.5 percent year over year in May to June.

AutoZone and O'Reilly have been battling in comp growth comparison with AutoZone growing flattish comps for its last four quarters and expectations of next year laps roughly by a three percent rate; O'Reilly increased from 2.5 percent in the last year to 5.7 percent over the next year.

Latest Ratings for AZO

DateFirmActionFromTo
Sep 2019MaintainsOutperform
Sep 2019MaintainsOutperform
Sep 2019MaintainsBuy

View More Analyst Ratings for AZO
View the Latest Analyst Ratings

Posted-In: David Schick StifelAnalyst Color Downgrades Analyst Ratings

 

Related Articles (ORLY + AZO)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LGIHBTIGReiterates65.0
NXSTBenchmarkMaintains150.0
ANIKFirst AnalysisDowngrades
HUNAlembic GlobalAssumes
POOLStephens & Co.Reiterates196.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

5 New Medical Technologies For Diabetics

NQ Mobile In Possible Short Squeeze; Muddy Waters Sticks To Guns